
Opinion|Videos|April 17, 2025
Patient Communication and Treatment Adherence in NMIBC
Experts discuss the potential impact of FDA-approved novel delivery systems on patients’ quality of life and treatment adherence in the management of non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If they are FDA approved, what impact are the novel delivery systems likely to have on patients’ quality of life? Treatment adherence?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












